LXEO Paula H Cholmondeley buys $105K worth of shares
Nov 27, 2024, 8:34 AM
-17.62%
What does LXEO do
Lexeo Therapeutics, a New York City-based genetic medicine company, focuses on therapies for hereditary and acquired diseases and recently went public on November 3, 2023. Its pipeline includes cardiovascular candidates LX2006 and LX2020, both undergoing clinical evaluation.
Paula H Cholmondeley bought 15,000 shares of LXEO on 25 November at $6.99 per share, worth a total of $105K. They now own 30,627 LXEO shares, or a 96% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
